Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.52 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | APEX1 | P27695 | 3/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.36 |
| ▸ | BBOX1 | O75936 | 4/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL324011 | 0.96 | ACHE (0.52) | ACHETBXAS1MEN1KMT2AAPEX1 | |
| Hydrochloric Acid SCHEMBL1703796 | 0.94 | ACHE (0.45) | ACHETBXAS1MEN1KMT2AAPEX1 | |
| Methacrylic Acid SCHEMBL6561454 | 0.90 | ACHE (0.52) | ACHETBXAS1APEX1ENPP2BBOX1 | |
| Hydrochloric Acid SCHEMBL8695365 | 0.88 | ACHE (0.45) | ACHETBXAS1APEX1ENPP2BBOX1 | |
| Hydrochloric Acid SCHEMBL8222907 | 0.88 | ACHE (0.45) | ACHETBXAS1APEX1ENPP2BBOX1 | |
| Hydrochloric Acid SCHEMBL9497105 | 0.88 | APEX1 (0.48) | ACHETBXAS1MEN1KMT2AAPEX1 | |
| Methacrylic Acid SCHEMBL159154 | 0.87 | ACHE (0.48) | ACHESMN1; SMN2ENPP2BBOX1ADRA2A | |
| Hydrochloric Acid SCHEMBL7765956 | 0.86 | ACHE (0.39) | ACHEAPEX1SMN1; SMN2LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL6846525 | 0.85 | ACHE (0.39) | ACHETBXAS1ENPP2APOBEC3AAPOBEC3G | |
| SCHEMBL7093817 | 0.84 | ACHE (0.41) | ACHEAPEX1SMN1; SMN2LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081210-B1 | PHARMACEUTICAL COMPOSITION OF CASR MODULATORS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2026-04-15 | — | — | EP | claimed |
| EP-3664782-B1 | CHOLESTYRAMINE PELLETS, ORAL CHOLESTYRAMINE FORMULATIONS AND MEDICAL USE THEREOF | ALBIREO AB (SE) | 2025-01-29 | — | — | EP | claimed |
| EP-3246048-B1 | BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC APPLICATIONS | CALM WATER THERAPEUTICS LLC (US) | 2024-04-03 | — | — | EP | claimed |
| EP-4090313-B1 | SUSTAINED RELEASE COMPOSITIONS COMPRISING LIOTHYRONINE | AMNEAL COMPLEX PRODUCTS RES LLC (US) | 2024-03-13 | — | — | EP | claimed |
| EP-3995135-B1 | PROLONGED RELEASE DOSAGE FORM OF TAPENTADOL L-(+)- TARTARIC ACID SALT | GRUENENTHAL GMBH (DE) | 2022-07-13 | — | — | EP | claimed |
| WO-2022101247-A1 | SUSTAINED RELEASE DOSAGE FORMS OF A SALT OF TAPENTADOL WITH L-(+)-TARTARIC ACID | Grünenthal GmbH (DE) | 2022-05-19 | — | — | WO | claimed |
| EP-3995135-A1 | PROLONGED RELEASE DOSAGE FORM OF TAPENTADOL L-(+)- TARTARIC ACID SALT | Grünenthal GmbH (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-3824881-B1 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | AMNEAL COMPLEX PRODUCTS RES LLC (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3628004-B1 | SELF-REGULATING OSMOTIC GASTRORETENTIVE DRUG DELIVERY SYSTEMS | AMNEAL COMPLEX PRODUCTS RES LLC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3609472-B1 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | KASHIV SPECIALTY PHARMACEUTICALS LLC (US) | 2020-12-30 | — | — | EP | claimed |
| EP-1694297-B1 | CONTROLLED RELEASE ANALGESIC SUSPENSIONS | MCNEIL PPC INC (US) | 2013-04-10 | — | — | EP | claimed |
| EP-1677760-B1 | CONTROLLED RELEASE ANALGESIC SUSPENSIONS | MCNEIL PPC INC (US) | 2013-01-02 | — | — | EP | claimed |
| EP-1765307-B1 | DRY-COATING PROCESS | MEPHA SCHWEIZ AG (CH) | 2012-11-21 | — | — | EP | claimed |
| EP-1421932-B1 | Polyacrylic film forming compositions | MCNEIL PPC INC (US) | 2010-09-22 | — | — | EP | claimed |
| EP-1169032-B1 | KETOPROFEN MICROGRANULES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS | ETHYPHARM SA (FR) | 2005-08-31 | — | — | EP | claimed |
| EP-0940136-B1 | Reducing agent from a plurality of components and process for permanent hair waving using it | OREAL (FR) | 2004-10-13 | — | — | EP | claimed |
| EP-0930061-B1 | Oxidizing agent from a plurality of components and process for permanent hair waving using it | OREAL (FR) | 2004-02-25 | — | — | EP | claimed |
| EP-0617972-B1 | Dermal therapeutic system based on a mixture of fusible polymethacrylates | ROEHM GMBH (DE) | 2003-07-09 | — | — | EP | claimed |
| EP-0759303-B1 | COLON-SPECIFIC DRUG RELEASE SYSTEM | YAMANOUCHI PHARMA CO LTD (JP) | 2002-10-16 | — | — | EP | claimed |
| EP-0761227-A1 | SOLID ANTACID AND PROCESS FOR PRODUCING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-03-12 | — | — | EP | claimed |